drugset / Trial / NCT00649779

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

NCT00649779

Phase 1 Completed 21 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-label

Summary

The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a single, oral 8 mg (1 x 8 mg) dose administered under fasting conditions.

Timeline

Start
2005-09
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 8 mg Oral

Indications

No indication recorded.